

## ASX Announcement

### Imugene Presents PD1-Vaxx Clinical Plan at the American Association for Cancer Research 2020 Annual Meeting

---

**SYDNEY, Australia, 27 April 2020:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Anthony Good will present the clinical plan for its PD-1 targeting cancer immunotherapy, PD1-Vaxx, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I, scheduled for 27th-28th April 2020.

The abstract was originally accepted for the AACR Annual Meeting to be held in San Diego, 24th-29th April prior to the event being rescheduled to a virtual event due to the ongoing COVID-19 pandemic.

The abstract (number 10333) will be presented by Dr Anthony Good, Imugene's Vice President of Clinical Research, virtually during the clinical session: VPO.CT01 - Phase I Clinical Trials from 9.00am Eastern Daylight Time, USA, on Monday, April 27<sup>th</sup>.

The abstract presentation is entitled "IMU-201-101 an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer", and was authored by Professor Pravin Kaumaya at the Ohio State University, Ohio, USA, Professor Tanios Bekaii-Saab at the Mayo Clinic, Arizona, USA, Dr Tri Phan, at St Vincent's Clinical School, UNSW, AUS, Dr Mark Marino, Dr Nick Ede & Dr Anthony Good from Imugene Limited.

The first-in-human, phase 1, multi-centre, dose escalation study of PD1-Vaxx, is targeting patients with non-small cell lung cancer and will be testing different doses of PD1-Vaxx as monotherapy and in combination with immune checkpoint inhibitors.

The primary objective of the phase 1 trial is to determine safety and an optimal biological dose as monotherapy and in combination with immune checkpoint inhibitors. Efficacy, tolerability and immune response will also be measured.

The abstract title can be viewed on the AACR website at:

<https://www.abstractsonline.com/pp8/#!/9045/presentation/10627>

The virtual presentation is also accessible via Imugene's website and YouTube channel:

[https://youtu.be/3dq5sEr\\_Gu0](https://youtu.be/3dq5sEr_Gu0)

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

Follow us on Twitter [@TeamImugene](#)

Like us on Facebook [@Imugene](#)

Connect with us on LinkedIn [@Imugene Limited](#)

## **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.